Vaxart
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 109
- Market Cap
- $202M
- Website
- http://www.vaxart.com
- Introduction
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.
Vaxart secures additional $4.6 M for COVID-19 pill vaccine trial
Vaxart, Inc. increased funding for its Phase 2b oral COVID-19 vaccine trial to $460.7M, aiming to enhance clinical materials and site readiness. Despite a modest stock gain, the company is seen as undervalued, with a focus on advancing its vaccine programs against COVID-19, Norovirus, and HPV.
Breakthrough Research: Ginger's Potential in Diabetes Treatment Revealed!
Researchers at PGI and NABI explored ginger's anti-obesity and anti-diabetic properties, isolating active components within synthetic exosomes for potential drug development. Challenges in repeated ginger extraction led to the use of synthetic exosomes, offering a practical solution. Mice studies and hybrid exosome development are ongoing, aiming for clinical trials at PGI.
Biotech policy to boost high-yield crops, bio-pesticides: Jitendra Singh
India implements exclusive biotechnology policy; Jitendra Singh inaugurates BRIC-NABI to enhance agri-food sector through advanced biotechnology, aiming for high-yield, disease-resistant crops and sustainable solutions.
Are Norovirus Vaccines on the Horizon?
Early-phase data on two norovirus vaccine candidates, an mRNA vaccine from Moderna (mRNA-1403) and an oral tablet, showed promising safety and immunogenicity results, with the mRNA vaccine moving to phase III trials.
Moderna's norovirus vaccine mRNA-1403 shows potential in Phase I/II trial
Moderna presented interim results for mRNA-1403, a norovirus vaccine candidate, at IDWeek 2024. The Phase I/II trial showed promising safety, reactogenicity, and immunogenicity, with robust antibody responses. Older adults were well-represented, addressing their high risk for NoV. A Phase III trial is underway, and mRNA-1403 is one of six NoV vaccine candidates in late-stage development.
Related Clinical Trials:
Multiple Project Vacancies for Life Sciences at NABI - Attend Walk-In-Interview
NABI offers multiple biotechnology project vacancies for MSc Life Sciences, Microbiology graduates. Positions include Junior Research Fellow, Project Associate I, and more, with varying durations and qualifications. Emoluments range from Rs. 31,000/- to Rs. 37,000/- per month plus HRA. Interested candidates must attend a walk-in interview on 29.10.2024 at NABI, Mohali.
Top 5 Infectious Disease News Stories Week of September 27-October 4
Healthcare workers saw 45% reduction in COVID-19 symptoms post-vaccination; MeMed BV test differentiates bacterial from viral infections; CDC warns of listeriosis linked to deli meats; Vaxart's oral COVID-19 vaccine trial aims to prevent symptomatic disease; fidaxomicin outperforms vancomycin in treating Clostridioides difficile infection.
Q4 2023 Vaxart Inc Earnings Call
Vaxart discussed its 2023 achievements, including progress in oral vaccine development for norovirus and COVID-19, highlighted by a $9.27M BARDA contract for a Phase IIb COVID-19 trial. The company emphasized the potential of its oral pill vaccines to offer advantages over injectables, such as ease of administration and mucosal immunity. Vaxart also announced the appointment of a new CEO, Steve Lo, and shared updates on financial results and future clinical trial plans.
© Copyright 2025. All Rights Reserved by MedPath